The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

키워드

참고문헌 (203)

1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
2. Younossi Z, "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
3. Byrne CD, "NAFLD: a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
4. Byrne CD, "NAFLD as a driver of chronic kidney disease", J Hepatol, 72, pp.785~801 (2020)
5. Targher G, "NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications", Gut, 69, pp.1691~1705 (2020)
6. NCD Risk Factor Collaboration (NCD-RisC), "Trends in adult bodymass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants", Lancet, 387, pp.1377~1396 (2016)
7. Jandhyala SM, "Role of the normal gut microbiota", World J Gastroenterol, 21, pp.8787~8803 (2015)
8. Segata N, "Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples", Genome Biol, 13, pp.R42~ (2012)
9. Azad MB, "Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study", BJOG, 123, pp.983~993 (2016)
10. Cox LM, "Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences", Cell, 158, pp.705~721 (2014)
11. Nobili V, "A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease", Arch Dis Child, 94, pp.801~805 (2009)
12. Rinninella E, "What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases", Microorganisms, 7, pp.14~ (2019)
13. Nagpal R, "Gut microbiome and aging: physiological and mechanistic insights", Nutr Healthy Aging, 4, pp.267~285 (2018)
14. Tap J, "Towards the human intestinal microbiota phylogenetic core", Environ Microbiol, 11, pp.2574~2584 (2009)
15. Claesson MJ, "Composition, variability, and temporal stability of the intestinal microbiota of the elderly", Proc Natl Acad Sci U S A, 108(Suppl 1), pp.4586~4591 (2011)
16. Salguero MV, "Dysbiosis of gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease", Exp Ther Med, 18, pp.3461~3469 (2019)
17. Dabke K, "The gut microbiome and metabolic syndrome", J Clin Invest, 129, pp.4050~4057 (2019)
18. Bouter KE, "Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction", Gastroenterology, 152, pp.1671~1678 (2017)
19. Wigg AJ, "The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis", Gut, 48, pp.206~211 (2001)
20. Le Roy T, "Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice", Gut, 62, pp.1787~1794 (2013)
21. Henao-Mejia J, "Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity", Nature, 482, pp.179~185 (2012)
22. Zeng H, "Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL", 6 mice fed a high-fat diet, 2013, pp.143, 627~631
23. Cano PG, "Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice", Obesity (Silver Spring), 21, pp.2310~2321 (2013)
24. Mazagova M, "Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice", FASEB J, 29, pp.1043~1055 (2015)
25. Spencer MD, "Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency", Gastroenterology, 140, pp.976~986 (2011)
26. Wong VW, "Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study", PLoS One, 8, pp.e62885~ (2013)
27. Mouzaki M, "Intestinal microbiota in patients with nonalcoholic fatty liver disease", Hepatology, 58, pp.120~127 (2013)
28. Zhu L, "Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH", Hepatology, 57, pp.601~609 (2013)
29. Raman M, "Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 11, pp.868~875.e3 (2013)
30. Loomba R, "Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease", Cell Metab, 25, pp.1054~1062.e5 (2017)
31. Schwimmer JB, "Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease", Gastroenterology, 157, pp.1109~1122 (2019)
32. Tsai MC, "Gut microbiota dysbiosis in patients with biopsy-proven nonalcoholic fatty liver disease: a cross-sectional study in Taiwan", Nutrients, 12, pp.820~ (2020)
33. Del Chierico F, "Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaomics-based approach", Hepatology, 65, pp.451~464 (2017)
34. Wang B, "Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease", Sci Rep, 6, pp.32002~ (2016)
35. Shen F, "Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease", Hepatobiliary Pancreat Dis Int, 16, pp.375~381 (2017)
36. Boursier J, "The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota", Hepatology, 63, pp.764~775 (2016)
37. De Filippis F, "High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome", Gut, 65, pp.1812~1821 (2016)
38. Simpson HL, "Review article: dietary fibre-microbiota interactions", Aliment Pharmacol Ther, 42, pp.158~179 (2015)
39. Lecerf JM, "Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties", Br J Nutr, 108, pp.1847~1858 (2012)
40. Veiga P, "Changes of the human gut microbiome induced by a fermented milk product", Sci Rep, 4, pp.6328~ (2014)
41. den Besten G, "The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism", J Lipid Res, 54, pp.2325~2340 (2013)
42. Hara H, "Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine", J Nutr, 129, pp.942~948 (1999)
43. den Besten G, "short-chain fatty acids protect against high-fat dietinduced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation", Diabetes, 64, pp.2398~2408 (2015)
44. Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest", Nature, 444, pp.1027~1031 (2006)
45. Schwiertz A, "Microbiota and SCFA in lean and overweight healthy subjects", Obesity (Silver Spring), 18, pp.190~195 (2010)
46. Kimura I, "The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43", Nat Commun, 4, pp.1829~ (2013)
47. Koruda MJ, "Parenteral nutrition supplemented with short-chain fatty acids:effect on the small-bowel mucosa in normal rats", Am J Clin Nutr, 51, pp.685~689 (1990)
48. Tappenden KA, "Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes", Dig Dis Sci, 43, pp.1526~1536 (1998)
49. Cani PD, "Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability", Gut, 58, pp.1091~1103 (2009)
50. Maslowski KM, "Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43", Nature, 461, pp.1282~1286 (2009)
51. Bollrath J, "Immunology. Feed your tregs more fiber", Science, 341, pp.463~464 (2013)
52. Rau M, "Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease", United European Gastroenterol J, 6, pp.1496~1507 (2018)
53. Brunt EM, "Histopathology of nonalcoholic fatty liver disease", World J Gastroenterol, 16, pp.5286~5296 (2010)
54. Yuan J, "Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae", Cell Metab, 30, pp.675~688.e7 (2019)
55. Cope K, "Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis", Gastroenterology, 119, pp.1340~1347 (2000)
56. Engstler AJ, "Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease", Gut, 65, pp.1564~1571 (2016)
57. Baker SS, "Role of alcohol metabolism in non-alcoholic steatohepatitis", PLoS One, 5, pp.e9570~ (2010)
58. Parlesak A, "Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease", J Hepatol, 32, pp.742~747 (2000)
59. Yao ZM, "Reduction in VLDL, but not HDL, in plasma of rats deficient in choline", Biochem Cell Biol, 68, pp.552~558 (1990)
60. Weltman MD, "Increased hepatocyte CYP2E1expression in a rat nutritional model of hepatic steatosis with inflammation", Gastroenterology, 111, pp.1645~1653 (1996)
61. Kirsch R, "Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies", J Gastroenterol Hepatol, 18, pp.1272~1282 (2003)
62. Wang Z, "Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease", Nature, 472, pp.57~63 (2011)
63. Dumas ME, "Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice", Proc Natl Acad Sci U S A, 103, pp.12511~12516 (2006)
64. Sohlenkamp C, "Biosynthesis of phosphatidylcholine in bacteria", Prog Lipid Res, 42, pp.115~162 (2003)
65. Geiger O, "Phosphatidylcholine biosynthesis and function in bacteria", Biochim Biophys Acta, 1831, pp.503~513 (2013)
66. Mao JW, "Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease", Int J Clin Exp Pathol, 8, pp.3648~3658 (2015)
67. Yang SQ, "Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis", Proc Natl Acad Sci U S A, 94, pp.2557~2562 (1997)
68. Harte AL, "Elevated endotoxin levels in non-alcoholic fatty liver disease", J Inflamm (Lond), 7, pp.15~ (2010)
69. Bergheim I, "Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin", J Hepatol, 48, pp.983~992 (2008)
70. Pendyala S, "A high-fat diet is associated with endotoxemia that originates from the gut", Gastroenterology, 142, pp.1100~1101.e2 (2012)
71. Deopurkar R, "Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of toll-like receptor-4 and suppressor of cytokine signaling-3", Diabetes Care, 33, pp.991~997 (2010)
72. Laugerette F, "Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation", J Nutr Biochem, 22, pp.53~59 (2011)
73. Cani PD, "Metabolic endotoxemia initiates obesity and insulin resistance", Diabetes, 56, pp.1761~1772 (2007)
74. Chen M, "Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling", Autophagy, 13, pp.1813~1827 (2017)
75. Mencin A, "Toll-like receptors as targets in chronic liver diseases", Gut, 58, pp.704~720 (2009)
76. Friedman SL, "A deer in the headlights: BAMBI meets liver fibrosis", Nat Med, 13, pp.1281~1282 (2007)
77. Takaki A, "Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)", Int J Mol Sci, 15, pp.7352~7379 (2014)
78. Tyrer PC, "Effects of bacterial products on enterocyte-macrophage interactions in vitro", Biochem Biophys Res Commun, 413, pp.336~341 (2011)
79. Rivera CA, "Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis", J Hepatol, 47, pp.571~579 (2007)
80. Spruss A, "Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice", Hepatology, 50, pp.1094~1104 (2009)
81. Dixon LJ, "Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis", PLoS One, 8, pp.e56100~ (2013)
82. Friedman SL, "Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH", Nat Rev Gastroenterol Hepatol, 10, pp.71~72 (2013)
83. Wree A, "NLRP3 inflammasome activation is required for fibrosis development in NAFLD", J Mol Med (Berl), 92, pp.1069~1082 (2014)
84. Pierantonelli I, "Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD", Sci Rep, 7, pp.12200~ (2017)
85. Porez G, "Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease", J Lipid Res, 53, pp.1723~1737 (2012)
86. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
87. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
88. Botham KM, "The effect of dietary fat on bile salt synthesis in rat liver", Biochim Biophys Acta, 752, pp.307~314 (1983)
89. Bertolotti M, "Regulation of hepatic cholesterol metabolism in the rat in vivo: effect of a synthetic fat-free diet on sterol synthesis and low-density lipoprotein transport", Biochim Biophys Acta, 1255, pp.293~300 (1995)
90. Koeth RA, "Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis", Nat Med, 19, pp.576~585 (2013)
91. Bennett BJ, "Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation", Cell Metab, 17, pp.49~60 (2013)
92. Parséus A, "Microbiota-induced obesity requires farnesoid X receptor", Gut, 66, pp.429~437 (2017)
93. Jiang C, "Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease", J Clin Invest, 125, pp.386~402 (2015)
94. Graf D, "Contribution of diet to the composition of the human gut microbiota", Microb Ecol Health Dis, 26, pp.26164~ (2015)
95. De Santis S, "Nutritional keys for intestinal barrier modulation", Front Immunol, 6, pp.612~ (2015)
96. Lerner A, "Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease", Autoimmun Rev, 14, pp.479~489 (2015)
97. Lima AA, "Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula", J Pediatr Gastroenterol Nutr, 40, pp.28~35 (2005)
98. Finamore A, "Zinc deficiency induces membrane barrier damage and increases neutrophil transmigration in Caco-2 cells", J Nutr, 138, pp.1664~1670 (2008)
99. Miele L, "Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease", Hepatology, 49, pp.1877~1887 (2009)
100. Verdam FJ, "Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis", J Clin Gastroenterol, 45, pp.149~152 (2011)
101. Yuan J, "Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis", J Gastroenterol Hepatol, 29, pp.1292~1298 (2014)
102. Caesar R, "Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling", Cell Metab, 22, pp.658~668 (2015)
103. de Groot P, "Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time", Gut, 69, pp.502~512 (2020)
104. Tirosh A, "The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans", Sci Transl Med, 11, pp.eaav0120~ (2019)
105. Schugar RC, "The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue", Cell Rep, 19, pp.2451~2461 (2017)
106. Parry SA, "Influence of dietary macronutrients on liver fat accumulation and metabolism", J Investig Med, 65, pp.1102~1115 (2017)
107. Mollard RC, "Dietary determinants of hepatic steatosis and visceral adiposity in overweight and obese youth at risk of type 2diabetes", Am J Clin Nutr, 99, pp.804~812 (2014)
108. Sathiaraj E, "A case-control study on nutritional risk factors in nonalcoholic fatty liver disease in Indian population", Eur J Clin Nutr, 65, pp.533~537 (2011)
109. Kuk JL, "Association between dietary fat intake, liver fat, and insulin sensitivity in sedentary, abdominally obese, older men", Appl Physiol Nutr Metab, 33, pp.239~245 (2008)
110. de Wit N, "Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine", Am J Physiol Gastrointest Liver Physiol, 303, pp.G589~G599 (2012)
111. Michael Shilling, "Antimicrobial Effects of Virgin Coconut Oil and Its Medium-Chain Fatty Acids on Clostridium difficile", Journal of Medicinal Food, 16(12), pp.1079~1085 (2013), 한국식품영양과학회[DOI]
112. Sheu CW, "Effects of fatty acids on growth and envelope proteins of Bacillus subtilis", J Bacteriol, 111, pp.516~524 (1972)
113. Zheng CJ, "Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids", FEBS Lett, 579, pp.5157~5162 (2005)
114. Scorletti E, "Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome*study", Hepatology, 60, pp.1211~1221 (2014)
115. Ghosh S, "Diets rich in n-6PUFA induce intestinal microbial dysbiosis in aged mice", Br J Nutr, 110, pp.515~523 (2013)
116. Mujico JR, "Changes in gut microbiota due to supplemented fatty acids in diet-induced obese mice", Br J Nutr, 110, pp.711~720 (2013)
117. Watson H, "A randomized trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota", Gut, 67, pp.1974~1983 (2018)
118. Ma J, "Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts", J Hepatol, 63, pp.462~469 (2015)
119. Donnelly KL, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease", J Clin Invest, 115, pp.1343~1351 (2005)
120. Softic S, "Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease", Dig Dis Sci, 61, pp.1282~1293 (2016)
121. Do MH, "High-glucose or -fructose diet cause changes of the gut microbiota and metabolic disorders in mice without body weight change", Nutrients, 10, pp.761~ (2018)
122. Ishimoto T, "High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase", Hepatology, 58, pp.1632~1643 (2013)
123. Cox CL, "Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight", obese humans, 2012, pp.9, 68~
124. Lanaspa MA, "Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver", J Biol Chem, 287, pp.40732~40744 (2012)
125. Lanaspa MA, "Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver", PLoS One, 7, pp.e47948~ (2012)
126. Mosca A, "Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents", J Hepatol, 66, pp.1031~1036 (2017)
127. Leung C, "Dietary glycotoxins exacerbate progression of experimental fatty liver disease", J Hepatol, 60, pp.832~838 (2014)
128. Snelson M, "Dietary advanced glycation end products: digestion, metabolism and modulation of gut microbial ecology", Nutrients, 11, pp.215~ (2019)
129. Zelber-Sagi S, "The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease:evidence and plausible mechanisms", Liver Int, 37, pp.936~949 (2017)
130. Ryan MC, "The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease", J Hepatol, 59, pp.138~143 (2013)
131. Godos J, "Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection", Int J Food Sci Nutr, 68, pp.18~27 (2017)
132. Rodriguez-Ramiro I, "Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms", Proc Nutr Soc, 75, pp.47~60 (2016)
133. Eliades M, "Vitamin D: a new player in non-alcoholic fatty liver disease?", World J Gastroenterol, 21, pp.1718~1727 (2015)
134. Harrison SA, "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.2485~2490 (2003)
135. Bahcecioglu IH, "Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet", Vet Med Int, 2010, pp.262179~ (2010)
136. Mitsou EK, "Adherence to the Mediterranean diet is associated with the gut microbiota pattern and gastrointestinal characteristics in an adult population", Br J Nutr, 117, pp.1645~1655 (2017)
137. Swithers SE, "A role for sweet taste: calorie predictive relations in energy regulation by rats", Behav Neurosci, 122, pp.161~173 (2008)
138. Margolskee RF, "T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1", Proc Natl Acad Sci U S A, 104, pp.15075~15080 (2007)
139. Mace OJ, "Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2", J Physiol, 582(1), pp.379~392 (2007)
140. Ruiz-Ojeda FJ, "Effects of sweeteners on the gut microbiota: a review of experimental studies and clinical trials", Adv Nutr, 10(suppl_1), pp.S31~S48 (2019)
141. Suez J, "Artificial sweeteners induce glucose intolerance by altering the gut microbiota", Nature, 514, pp.181~186 (2014)
142. Trocho C, "Formaldehyde derived from dietary aspartame binds to tissue components in vivo", Life Sci, 63, pp.337~349 (1998)
143. Imaizumi K, "Effects of xylooligosaccharides on blood glucose, serum and liver lipids and cecum short-chain fatty acids in diabetic rats", Agric Biol Chem, 55, pp.199~205 (1991)
144. Zhou J, "Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance", PLoS One, 9, pp.e87161~ (2014)
145. Santamarina AB, "Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in dietinduced obesity mice", J Nutr Biochem, 26, pp.1348~1356 (2015)
146. Kuzu N, "Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet", J Gastroenterol Hepatol, 23, pp.e465~e470 (2008)
147. Nakamoto K, "Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis", J Clin Biochem Nutr, 44, pp.239~246 (2009)
148. 서대방, "Fermented Green Tea Extract Alleviates Obesity and Related Complications and Alters Gut Microbiota Composition in Diet-Induced Obese Mice", Journal of Medicinal Food, 18(5), pp.549~556 (2015), 한국식품영양과학회[DOI]
149. Hong Byun E, "TLR4 signaling inhibitory pathway induced by green tea polyphenol epigallocatechin-3-gallate through 67-kDa laminin receptor", J Immunol, 185, pp.33~45 (2010)
150. Jovanovic S, "Antioxidant potential of gallocatechins. A pulse radiolysis and laser photolysis study", J Am Chem Soc, 117, pp.9881~9888 (1995)
151. Shen G, "Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL", 6J mice and C57BL, Nrf2 (-, pp.-)mice, Pharm Res[DOI]
152. Pezeshki A, "The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease", Int J Prev Med, 7, pp.28~ (2016)
153. Imatoh T, "Coffee but not green tea consumption is associated with prevalence and severity of hepatic steatosis: the impact on leptin level", Eur J Clin Nutr, 69, pp.1023~1027 (2015)
154. Molloy JW, "Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis", Hepatology, 55, pp.429~436 (2012)
155. Vitaglione P, "Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins", Hepatology, 52, pp.1652~1661 (2010)
156. Ding M, "Caffeinated and decaffeinated coffee consumption and risk of type 2diabetes: a systematic review and a dose-response meta-analysis", Diabetes Care, 37, pp.569~586 (2014)
157. Arion WJ, "Chlorogenic acid and hydroxynitrobenzaldehyde:new inhibitors of hepatic glucose 6-phosphatase", Arch Biochem Biophys, 339, pp.315~322 (1997)
158. Wijarnpreecha K, "Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 29, pp.e8~e12 (2017)
159. Feld JJ, "I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis", F1000Res, 4, pp.95~ (2015)
160. Nakayama T, "Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses", FEMS Microbiol Lett, 343, pp.161~168 (2013)
161. Jaquet M, "Impact of coffee consumption on the gut microbiota: a human volunteer study", Int J Food Microbiol, 130, pp.117~121 (2009)
162. Hamaguchi M, "Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women", World J Gastroenterol, 18, pp.237~243 (2012)
163. Yang JD, "Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis", Hepatology, 59, pp.1406~1414 (2014)
164. Kojima S, "Increase in the prevalence of fatty liver in Japan over the past 12 years:analysis of clinical background", J Gastroenterol, 38, pp.954~961 (2003)
165. Park SH, "Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults", J Gastroenterol Hepatol, 21(1), pp.138~143 (2006)
166. Zhou YJ, "Prevalence of fatty liver disease and its risk factors in the population of South China", World J Gastroenterol, 13, pp.6419~6124 (2007)
167. Ventura-Clapier R, "Mitochondria: a central target for sex differences in pathologies", Clin Sci (Lond), 131, pp.803~822 (2017)
168. Skubic C, "Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs", Expert Opin Drug Metab Toxicol, 14, pp.831~841 (2018)
169. Frankenfeld CL, "Relationship of obesity and high urinary enterolignan concentrations in 6806 children and adults: analysis of National Health and Nutrition Examination Survey data", Eur J Clin Nutr, 67, pp.887~889 (2013)
170. Nakatsu CH, "Fecal bacterial community changes associated with isoflavone metabolites in postmenopausal women after soy bar consumption", PLoS One, 9, pp.e108924~ (2014)
171. Frankenfeld CL, "Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein", Eur J Clin Nutr, 68, pp.526~530 (2014)
172. Antharam VC, "Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea", J Clin Microbiol, 51, pp.2884~2892 (2013)
173. Menon R, "Diet complexity and estrogen receptor β status affect the composition of the murine intestinal microbiota", Appl Environ Microbiol, 79, pp.5763~5773 (2013)
174. Org E, "Sex differences and hormonal effects on gut microbiota composition in mice", Gut Microbes, 7, pp.313~322 (2016)
175. Jena PK, "Western diet-induced dysbiosis in farnesoid X receptor knockout mice causes persistent hepatic inflammation after antibiotic treatment", Am J Pathol, 187, pp.1800~1813 (2017)
176. Xie G, "Sexdependent effects on gut microbiota regulate hepatic carcinogenic outcomes", Sci Rep, 7, pp.45232~ (2017)
177. Paolella G, "Gutliver axis and probiotics: their role in non-alcoholic fatty liver disease", World J Gastroenterol, 20, pp.15518~15531 (2014)
178. D’Haens GR, "Fecal microbial transplantation for diseases beyond recurrent clostridium difficile infection", Gastroenterology, 157, pp.624~636 (2019)
179. Kootte RS, "Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition", Cell Metab, 26, pp.611~619.e6 (2017)
180. Vrieze A, "Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome", Gastroenterology, 143, pp.913~916.e7 (2012)
181. Allegretti JR, "Effects of fecal microbiota transplantation with oral capsules in obese patients", Clin Gastroenterol Hepatol, 18, pp.855~863.e2 (2020)
182. Fischer M, "Stool donor body mass index does not affect recipient weight after a single fecal microbiota transplantation for clostridium difficile Infection", Clin Gastroenterol Hepatol, 16, pp.1351~1353 (2018)
183. Yu EW, "Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebocontrolled pilot trial", PLoS Med, 17, pp.e1003051~ (2020)
184. Craven L, "Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial", Am J Gastroenterol, 115, pp.1055~1065 (2020)
185. Malaguarnera M, "Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis", Dig Dis Sci, 57, pp.545~553 (2012)
186. Shavakhi A, "Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial", Int J Prev Med, 4, pp.531~537 (2013)
187. Wong VW, "Treatment of nonalcoholic steatohepatitis with probiotics. A proofof-concept study", Ann Hepatol, 12, pp.256~262 (2013)
188. Alisi A, "Randomized clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 39, pp.1276~1285 (2014)
189. Eslamparast T, "Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study", Am J Clin Nutr, 99, pp.535~542 (2014)
190. Asgharian A, "The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial", Int J Prev Med, 7, pp.59~ (2016)
191. Ferolla SM, "Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis", Nutrients, 8, pp.397~ (2016)
192. Famouri F, "Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents", J Pediatr Gastroenterol Nutr, 64, pp.413~417 (2017)
193. Manzhalii E, "Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial", J Dig Dis, 18, pp.698~703 (2017)
194. Mofidi F, "Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomized, double-blind, placebocontrolled, clinical trial", Br J Nutr, 117, pp.662~668 (2017)
195. Bakhshimoghaddam F, "Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial", J Nutr, 148, pp.1276~1284 (2018)
196. Kobyliak N, "Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study", Minerva Med, 109, pp.418~428 (2018)
197. Kobyliak N, "A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients:evidence from a randomized clinical trial", J Gastrointestin Liver Dis, 27, pp.41~49 (2018)
198. Saba Sayari, "Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 24(3), pp.331~338 (2018), 대한간학회
199. Wang W, "Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease", Zhonghua Nei Ke Za Zhi, 57, pp.101~106 (2018)
200. Ahn SB, "Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease", Sci Rep, 9, pp.5688~ (2019)
201. Duseja A, "High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomized, double-blind, proof of concept study", BMJ Open Gastroenterol, 6, pp.e000315~ (2019)
202. Scorletti E, "Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease", Gastroenterology, 158, pp.1597~1610.e7 (2020)
203. Jennison E, "Diagnosis and management of non-alcoholic fatty liver disease", Postgrad Med J, 95, pp.314~322 (2019)

관련 논문AI추천